Business: Phase 2 biotech developing allogeneic T cell therapies for viral diseases. Fathom Holdings - Cary, N.C., 2.5 million shares, priced $7-$9, ...
News
- Initial public offerings scheduled to debut next week
- Coronavirus makes changes that cause cells not to recognize it
The University of Texas Health Science Center at San Antonio, also ... health professions and graduate biomedical sciences have graduated more ...
- Pepcid as a virus remedy? Trump admin's $21M gamble fizzled
Federal pandemic response scientists at the Biomedical Advanced Research and Development Authority, or BARDA, were shut out of these early ...
- Trump to visit North Carolina, cite work on COVID-19 vaccine
The biotechnology facility Trump will visit is the FUJIFILM Diosynth Biotechnologies' Innovation Center in Morrisville, a suburb of Raleigh. The White ...
- News of potential COVID-19 vaccine met with optimism, caution
SAN ANTONIO – News that Pfizer Pharmaceutical has agreed to sell the ... Schlesinger, president and CEO of Texas Biomedical Research Institute.